Findings from HERACLES A Study
Findings from HERACLES A Study
For patients with metastatic colorectal cancer (mCRC), the HERACLES A Study showed that, Guardant360® can detect actionable mutations that can result in selection of targeted therapy and may lead to better patient outcomes1.
Guardant360® showed a correlation between clinical outcomes and adjusted ERBB2 copy number. ERBB2 (HER2) amplification is a recommended biomarker in mCRC.
BOR* in baseline plasma ERBB2 positive metastatic CRC1
PFS by ERBB2 adjusted plasma copy number (pCN)1
97.9% sensitivity for
ERBB2-amplification
detection1
Reference:
1. Siravegna G, Sartore-Bianchi A, Nagy RJ et al. Plasma HER2 (ERBB2) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer. Clin Cancer Res. 2019 May 15;25(10):3046-3053. doi: 10.1158/1078-0432.CCR-18-3389.
Address:
21 Biopolis Road,
# 03-28, Nucleos,
Singapore 138567.
Telephone:
+65 6018 8504
WhatsApp Hotline:
+65 8940 0360
Email:
clientservicesamea@guardanthealth.com
biopharma_AMEA@guardanthealth.com
Media inquiries:
Guardant Health Japan Corp.
Address:
9F Tokyo Portcity Takeshiba Office Tower,
1-7-1 Kaigan, Minato-ku,
Tokyo, 105-7590, Japan
© 2023 Guardant Health AMEA ALL RIGHTS RESERVED